Raptor Pharmaceutical Corp (RPTP)

9.00
0.00 (0.00)
NASDAQ : Health Care
Prev Close 9.00
Open 8.95
Day Low/High 8.95 / 9.05
52 Wk Low/High 2.94 / 14.90
Volume 753.41K
Avg Volume 2.45M
Exchange NASDAQ
Shares Outstanding 85.31M
Market Cap 767.76M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting RPTP Put For October 19th

Interesting RPTP Put For October 19th

Investors in Raptor Pharmaceuticals Corp. saw new options begin trading this week, for the October 19th expiration.

Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update And Second Quarter 2013 Financial Results

Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update And Second Quarter 2013 Financial Results

Early Launch Metrics Show Anticipated Strong PROCYSBI Demand

Raptor's PROCYSBI(TM) Now Commercially Available In The U.S. For Nephropathic Cystinosis Patients

Raptor's PROCYSBI(TM) Now Commercially Available In The U.S. For Nephropathic Cystinosis Patients

Prescription Claims Have Been Approved by Payors and Are Now Being Filled at Accredo Specialty Pharmacy

5 Stocks Under $10 Set to Surge

5 Stocks Under $10 Set to Surge

These under-$10 stocks look poised to trade higher from current levels.

Raptor's FDA Approval Is New Test for Orphan Drug Pricing

Raptor's FDA Approval Is New Test for Orphan Drug Pricing

Will insurers pay more for a orphan disease drug only because it's more convenient?

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

A list of stocks with drugs expecting FDA decisions in 2013

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

First 90 Days of 2013 Are Live or Die For These Biotech Stocks

Clinical trials, drug launches and FDA approval decisions fill the early 2013 biotech calendar.

Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold

Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies